The pharmaceutical company Antibiotice S.A. in Iasi ended H1 of 2016 with sales of RON 143.8 million, up 9 percent compared to the same period last year, while net profit increased by almost 8 percent to RON 16.4 million, company’s financial report, published on the Bucharest Stock Exchange, reveals on Monday.
The revenues from the domestic market went up by 3.5 percent during the first six months, while gross profit has increased by 13 percent to RON 18.85 million. Also, the turnover was 3.5 percent higher than the same period of last year, reaching RON 89.4 million.
At the same time, Antibiotice earns RON 54.5 million from the external markets sales in H1, an advance of 18 percent compared with 2015 when the revenues were RON 46.26 million. The main increase was recorded in the US market, where deliveries have doubled compared to the same period in 2015.
Just recently, six trucks with injectable anti-infectives with the label ‘made by Antibiotice for the U.S.A’ went to the Port of Constanta, being the largest delivery of finished products in the US, a strategic market for Romanian pharmaceutical company, from the beginning of 2016.
Also, Antibiotice’s exports in Europe doubled, while in Russia, Middle East, Southeast Asia and CIS countries the exports were mostly at the level from 2015 influenced by some geo-political factors from some markets.
The highest increases were registered for products such as injections (used in hospitals to treat infections), capsules and suppositories.
According to Cegedim market research company, Antibiotice climbed one position in H1 compared to 2015 and ranks 12th among the 300 pharmaceutical companies operating on domestic market.
“In this context, at the end of the first half of 2016, Antibiotice is among the elite of the five companies in the top 20 whose portfolio registers increases compared to the same period in 2015,” Cegedim notes.